Reframe Daily: Safer heart scans, migraine relief without drugs, and a new dual Salmonella vaccine

Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible healthtech updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: Safer heart-scan tech, avalanche gear that keeps people breathing longer, open-label placebos easing migraines, dual immunotherapy shrinking skin cancers, and a combo vaccine guarding against typhoid and Salmonella.

Pop in the Discord to chat about health →
https://forms.gle/tN3oabFTsDF21VnS8

Weekly personal shares from Christin here →
http://christin.substack.com/

Good news: Hospitals can safely swap a throat scope for a gentler heart-catheter view before AF ablation—same protection, fewer hassles for patients.

Intracardiac vs Transesophageal Echocardiography in Atrial Fibrillation Ablation: A Randomized Clinical Trial

Market readiness: 😀😀😀😀😀 (both imaging methods are widely available now; this RCT supports an immediate practice change). 

Good news: A backpack safety device helped trapped “avalanche victims” breathe longer in a randomized trial—buying rescuers more time.

Respiratory Gas Shifts to Delay Asphyxiation in Critical Avalanche Burial: A Randomized Clinical Trial

Market readiness: 😀😀😀😀 (hardware exists and was used in the trial; broad adoption needs training and guideline uptake). 

Good news: A no-deception “open-label placebo” add-on improved quality of life and disability in migraine—an option clinics can try now for willing patients.

Open-Label Placebos as Adjunct for the Preventive Treatment of Migraine: A Randomized Clinical Trial

Market readiness: 😀😀😀😀 (no new drug to approve; implementation depends on clinician protocols and patient education). 

Good news: Before surgery, combining ipilimumab + nivolumab shrank/controlled cutaneous squamous-cell cancers in a phase 2 study—hinting some patients could avoid more invasive treatments.

Neoadjuvant ipilimumab plus nivolumab in resectable cutaneous squamous cell carcinoma

Market readiness: 😀😀😀 (drugs are approved, but this neoadjuvant use needs larger trials and guideline changes). 

Good news: A first-in-human combo vaccine targeting typhoid and invasive non-typhoidal Salmonella was safe and raised strong antibodies—promising for global gut-infection prevention.

Safety and immunogenicity of a combination typhoid and non-typhoidal Salmonella polysaccharide conjugate vaccine in a phase 1 trial

Market readiness: 😀😀 (phase 1 only; needs phase 2/3 efficacy and manufacturing scale-up).

Thank you for taking the time to take care of yourself and your loved ones.